[Skip to Navigation]
Sign In
January 20, 2022

Changes Reflecting Corrections to Related Article

JAMA Oncol. 2022;8(3):484. doi:10.1001/jamaoncol.2021.7317

The Editorial “Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine,”1 published online on July 5, 2018, and in the November 2018 issue of JAMA Oncology, has been corrected online to reflect corrections made to the related article,2 as explained in a Letter to the Editor.3 These corrections do not change the conclusions or interpretations of the related article2 or the Editorial.1

Roberts  MC.  Implementation challenges for risk-stratified screening in the era of precision medicine.   JAMA Oncol. 2018;4(11):1484-1485. doi:10.1001/jamaoncol.2018.1940PubMedGoogle ScholarCrossref
Pashayan  N, Morris  S, Gilbert  FJ, Pharoah  PDP.  Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model.   JAMA Oncol. 2018;4(11):1504-1510. doi:10.1001/jamaoncol.2018.1901PubMedGoogle ScholarCrossref
Pashayan  N, Pharoah  PDP.  Concerns about methods used in modeling study of risk-stratified screening for breast cancer.   JAMA Oncol. Published online January 20, 2022. doi:10.1001/jamaoncol.2021.7311Google Scholar